Natera, Inc. (NASDAQ:NTRA – Get Free Report) has been given an average recommendation of “Buy” by the sixteen brokerages that are presently covering the company, Marketbeat Ratings reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $125.69.
A number of equities analysts have weighed in on NTRA shares. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Leerink Partners raised their price target on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th.
Read Our Latest Analysis on NTRA
Natera Stock Down 0.1 %
Insider Activity at Natera
In other news, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the transaction, the insider now owns 287,441 shares in the company, valued at $34,783,235.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the sale, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 4,523 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the transaction, the chief executive officer now directly owns 191,163 shares in the company, valued at approximately $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is owned by insiders.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the 2nd quarter valued at $28,000. Quarry LP lifted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the period. Covestor Ltd boosted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. Finally, Tobam purchased a new stake in shares of Natera during the second quarter worth about $74,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
- Five stocks we like better than Natera
- Using the MarketBeat Dividend Yield Calculator
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- What is the Euro STOXX 50 Index?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Retail Stocks Investing, Explained
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.